Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Primary care physicians (PCPs) play a key role in treating young patients as they progress through the "atopic march" from atopic dermatitis through food allergy, asthma, and allergic rhinitis.

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...

Medscape Medical News, October 16, 2024 PCPs Are Key to Halting Atopic March Families rely on PCPs to manage, or ideally prevent, the progression of allergic disorders in young patients.

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner. The company has claimed across-the ...

Today marks the 50th anniversary of the 1963 March on Washington for Jobs and Freedom. The event is most famous for the "I Have a Dream" speech delivered by Martin Luther King Jr. from the steps ...

The most common form of eczema is atopic dermatitis, and the terms are often used interchangeably. The condition often crops up during childhood, experts said. And while some people outgrow it ...

The annual meeting of the American College of Allergy, Asthma & Immunology was held from Oct. 24 to 28 in Boston, drawing ...

Given atopic dermatitis' negative impacts on quality of life among adolescents, including increased suicidality, "there remains a need for treatments available to this population," the authors ...